Unveiling the safety profile of lecanemab: A comprehensive analysis of adverse events using FDA adverse event reporting system data
Journal of Alzheimer’s Disease · 2025
DOI: 10.1177/13872877241307246 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Alzheimer’s Disease, 2025. Verfasst von Wukun Ge und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy, Ninghai First Hospital, Ninghai, Ningbo, China. Hauptthemen laut MEDLINE: Adverse Drug Reaction Reporting Systems, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 36 Literaturangaben.
Themen: Patientensicherheit
Abstract (Originalsprache)
Background
Lecanemab, a novel monoclonal antibody targeting amyloid-β, has shown promise in treating Alzheimer's disease. Comprehensive post-marketing safety data analysis is crucial to understand its real-world risk profile.
Objective
This study aimed to evaluate the safety profile of lecanemab using data from the FDA Adverse Event Reporting System (FAERS), with a focus on nervous system disorders and amyloid-related imaging abnormalities.
Methods
We conducted a disproportionality analysis using the FAERS database to evaluate the safety signals associated with lecanemab. Reporting odds ratio (ROR), proportional reporting ratio, empirical Bayesian geometric mean, and information component were calculated at both system organ class (SOC) and preferred term (PT) levels. Additionally, we performed a time-to-onset analysis using Weibull shape parameter estimation.
Results
Analysis at the SOC level revealed significant signals for nervous system disorders (ROR: 7.32, 95% CI: 6.69–8.00). At the PT level, strong signals were observed for amyloid-related imaging abnormalities, particularly those associated with microhemorrhages and oedema (ROR: 4122.81 and 3922.78, respectively). Headache was the most frequently reported adverse event (200 cases), followed by chills (107 cases) and fatigue (97 cases). Time-to-onset analysis showed a median time of 33 days (range: 1–1283) for all adverse events, with neurological events occurring slightly later (median: 42 days, range: 1–1260).
Conclusions
Our findings highlight a distinct safety profile for lecanemab, with a predominant impact on the nervous system and a notable association with imaging abnormalities. These results underscore the importance of vigilant monitoring and further research to optimize the risk-benefit profile of lecanemab in clinical practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Pharmacy, Ninghai First Hospital, Ninghai, Ningbo, China.
- Department of Pharmacy, Women and Children's Hospital of Ningbo University, Ningbo, China.
ORCID-Profile: Wukun Ge, Peizhi Mao
Zitieren
APA
Ge, W., Yan, Y., Hu, Y., Lin, S., & Mao, P. (2025). Unveiling the safety profile of lecanemab: A comprehensive analysis of adverse events using FDA adverse event reporting system data. Journal of Alzheimer’s Disease. https://doi.org/10.1177/13872877241307246
Vancouver
Ge W, Yan Y, Hu Y, Lin S, Mao P. Unveiling the safety profile of lecanemab: A comprehensive analysis of adverse events using FDA adverse event reporting system data. Journal of Alzheimer’s Disease. 2025. doi:10.1177/13872877241307246
BibTeX
@article{Ge2025,
author = {Ge, Wukun and Yan, Yingyan and Hu, Yaoyao and Lin, Shuainan and Mao, Peizhi},
title = {Unveiling the safety profile of lecanemab: A comprehensive analysis of adverse events using FDA adverse event reporting system data},
journal = {Journal of Alzheimer’s Disease},
year = {2025},
doi = {10.1177/13872877241307246}
}
EUVIMED